A recall announcement warned consumers the undeclared ingredients ‘may lower blood pressure to dangerous levels’ ...
Dr Cho Li Wei, leading LW Cho Endocrine Clinic, is marking 23 years in endocrinology and 27 years in clinical practice, with a continued focus on bridging language gaps in specialist medical care. The ...
Nigeria has scored zero on obesity treatment and physical activity in a new global assessment of how countries are responding ...
Drap says Pakistan has sufficient drug stocks for three months, with alternative supply routes being explored • Pharmaceutical ...
The new Center for Excellence in Diabetes will focus on research, clinical trials and prevention for a disease affecting about one in six people in the San Antonio area.
The evolving relationship between GLP-1 medications and protein consumption presents both challenges and opportunities for ...
Pacific research partnership offers a glimpse of how the obesity drug boom could transform global health – and raise difficult questions in the process.
Glaucoma affects millions in India and often goes undiagnosed. Experts explain how early detection, healthy lifestyle habits and family support can help manage the condition.
By GEORGIA GARVEY Syndicated columnist I’ve been hearing a lot lately about how it’s “taking the easy way out” to use GLP-1s ...
In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...
The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or obesity in a small study.
Glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes or weight management is associated with a lower risk of developing colon cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results